Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Preliminary results for ropeginterferon alfa-2b in prefibrotic primary low/intermediate-1 risk myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)
Phase I study evaluating selinexor + ruxolitinib in previously untreated myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)
Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on management strategies for MF
Results from phase II REFINE cohort 3 evaluating navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis, from ASH 2022 and reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.